Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vascular disrupting agents.

M J Pilat1, P M Lorusso

  • 1Department of Internal Medicine, Division of Hematology/Oncology, Karmanos Cancer Institute, Detroit, Michigan 48201, USA.

Journal of Cellular Biochemistry
|August 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.

British journal of cancer·2017
Same author

BET inhibitors: a novel epigenetic approach.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors.

Investigational new drugs·2013
Same author

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).

British journal of cancer·2011
Same journal

Tricarboxylic Acid (TCA) Cycle Enzyme Alpha-Ketoglutarate Dehydrogenase (KGDH) as a Nexus for the Regulation of Macrophage Polarization.

Journal of cellular biochemistry·2026
Same journal

Zinc Finger Proteins as Regulators of Organ Fibrosis.

Journal of cellular biochemistry·2026
Same journal

Intrinsic Disorder Status in Human Proteins Interacting With SARS-CoV-2 Proteins: Insights From Five Years of Translational Research.

Journal of cellular biochemistry·2026
Same journal

The Effect of Protein Tagging on Aggregation and Phase Separation.

Journal of cellular biochemistry·2026
Same journal

TRIM32 Alleviates the Inflammation in Spinal Cord Injury Progression Through Inducing the Ubiquitination Degradation of TLR4.

Journal of cellular biochemistry·2026
Same journal

Bedaquiline Binding at the Leading Site of Mycobacterium tuberculosis ATP Synthase Induces Distinct Structural and Dynamic Changes.

Journal of cellular biochemistry·2026
See all related articles

Vascular disrupting agents (VDAs) target established tumor blood vessels, causing necrosis. VDAs show promise against advanced cancers, especially when combined with treatments targeting remaining tumor cells.

Area of Science:

  • Oncology
  • Vascular Biology
  • Drug Development

Background:

  • Solid tumor growth and metastasis depend on a functional vascular supply.
  • Tumor angiogenesis, the formation of new blood vessels, is crucial for tumor progression.
  • Targeting tumor vasculature is a key strategy in cancer therapy.

Purpose of the Study:

  • To review the role of vascular disrupting agents (VDAs) in cancer treatment.
  • To compare VDAs with antiangiogenic agents.
  • To explore the potential of VDAs in combination therapies.

Main Methods:

  • Review of existing research on VDAs and antiangiogenic agents.
  • Analysis of VDA mechanisms, efficacy, and limitations.
  • Discussion of VDA classification (ligand-bound and small molecule).

Related Experiment Videos

Main Results:

  • VDAs target established tumor vasculature, leading to ischemia and necrosis.
  • VDAs demonstrate more immediate effects than antiangiogenic agents and may be effective in advanced disease.
  • Both VDA types induce tumor core necrosis but leave a viable rim of tumor cells.

Conclusions:

  • VDAs are a distinct class of antitumor agents targeting existing tumor vasculature.
  • VDAs show potential efficacy, particularly in advanced or bulky tumors.
  • Combination therapy, pairing VDAs with agents targeting the peripheral tumor rim, is a promising strategy.